The Impact of Patient Characteristics and Tumor Biology on the Accuracy of Preoperative Staging of Colon Cancer in Denmark. A Nationwide Cohort Study

Malene Roland V. Pedersen 1,2,3,*, Søren Rafael Rafaelsen 1,2,3, Jan Lindebjerg 2,3,4, Torben Frøstrup Hansen 2,3,5 and Hans Bjarke Rahr 2,3,6

1 Department of Radiology, Vejle Hospital, University Hospital of Southern Denmark, DK-7100 Vejle, Denmark; Soeren.Rafael.Rafaelsen@rsyd.dk
2 Department of Regional Health Research, University of Southern Denmark, DK-7100 Vejle, Denmark; jan.lindebjerg@rsyd.dk (J.L.); Torben.Hansen@rsyd.dk (T.F.H.); hans.rahr@rsyd.dk (H.B.R.)
3 Danish Colorectal Cancer Center South, Vejle Hospital, University Hospital of Southern Denmark, DK-7100 Vejle, Denmark
4 Department of Pathology, Vejle Hospital, University Hospital of Southern Denmark, DK-7100 Vejle, Denmark
5 Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, DK-7100 Vejle, Denmark
6 Department of Surgery, Vejle Hospital, University Hospital of Southern Denmark, DK-7100 Vejle, Denmark

* Correspondence: Malene.Roland.Vils.Pedersen@rsyd.dk; Tel.: +45-7940-5300

Simple Summary: The roles of mismatch repair and other colon tumor characteristics were investigated in a nationwide registry study with data extracted from the Danish Colorectal Cancer Group. Mismatch repair can arise during DNA replication. In this study, 6102 patients were included with a median age of 72 (range 23–97 years). The mismatch repair was deficient in 24% and proficient in 76%. Mismatch repair deficiency impacted the accuracy of the preoperative staging of colon cancer. In the future, mismatch repair status should be taken into consideration in the clinical staging of colon cancer.

Abstract: Background: Colon cancer is a common disease in western populations. The aim of this study was to assess the impact of mismatch repair (MMR) deficiency and other patient and tumor characteristics on the accuracy of preoperative staging by comparing histopathological T- and N-categories of the resected specimen with the preoperative clinical stage in a nationwide cohort of patients treated for colon cancer by elective bowel resection with curative intent. Methods: A registry study of a cohort extracted from the Danish Colorectal Cancer Group (DCCG) database, which holds prospective data on all new cases of colon and rectum cancer in Denmark. Patients diagnosed with colon cancer and treated with an elective bowel resection with curative intent in the years 2016–2019 were analyzed. Results: A total of 6102 patients were included (n = 3161 (52%) men and n = 2941 (48%) women) with a median age of 72 years (range 23–97 years). MMR was deficient in 24% of the patients and proficient in 76%. MMR deficiency, tumor sidedness and histopathological type were significant predictors of the accuracy of preoperative staging of colon cancer in univariate and multivariate analysis. MMR status in particular showed a strong impact on the risk of overstaging. Conclusions: MMR deficiency, but also tumor sidedness and to some degree histopathological type, impacted the accuracy of preoperative staging of colon cancer. MMR status should be taken into consideration in everyday clinical staging.

Keywords: mismatch repair; colon cancer; registry study; tumor staging
1. Introduction

Colon cancer is a common disease in the Western world [1,2]. Most patients are treated by surgery, but very often in combination with pre- and/or post-operative chemotherapy and biological treatment. Treatment regimens are becoming increasingly complex, and accurate staging before treatment is crucial. Previous studies have shown limited accuracy of the standard diagnostic workup with contrast-enhanced computed tomography (CT) scans, particularly with regard to involvement of regional lymph nodes (N-category), which is often overestimated [3–6]. Recently, Erbs and colleagues found overstaging with regard to the N-category to be more common in patients whose colon tumors were mismatch repair (MMR) deficient (dMMR) compared with patients with MMR proficient (pMMR) tumors [7]. The study was a single-center series of patients retrospectively reviewed by an expert radiologist; however, it seems warranted to elucidate the impact of MMR status on routine clinical practice by conducting a larger, population-based study. Other patient and tumor characteristics, such as age, sex, body mass index (BMI) and tumor location (left vs. right colon), may also influence the accuracy of preoperative staging. Two recent Swedish studies were not able to demonstrate this unequivocally, but this may be because only Kappa statistics were used [8,9]. Since MMR status may be associated with both sidedness and histopathology, we suggest that adjusted, separate multivariate analysis of under- and over-staging may provide new and more useful information. Other plausible predictors for correct staging, e.g., histopathological type and discussion at a multidisciplinary team conference (MDT), should be included as potential covariates. A detailed understanding of CT performance is an essential basis for both further technical improvements and the current considerations on replacing CT as the standard modality with other imaging modalities that seem to perform better in some respects [10–16].

The aim of this study was to assess the impact of MMR deficiency and other patient and tumor characteristics on the accuracy of preoperative T and N staging by comparing the preoperative T- and N-categories (cTNM) with the histopathological T- and N-cATEGORIES of the resected specimen (pTNM) in a nationwide cohort of patients treated for colon cancer by elective bowel resection with curative intent.

2. Materials and Methods

The study was approved locally by the local National Data Protection Agency. According to national law, the current study did not require patient consent or approval by the National Health Research Ethics Committee since there was no biomedical intervention. Permission to use the data was granted by the national quality assurance authority (Regionernes Kliniske Kvalitetsudviklingsprogram, RKKP) (No. DCCG-2020-10-14).

2.1. Design and Data Sources

This was a register-based study of a patient cohort extracted from the Danish Colorectal Cancer Group (DCCG) database [17]. All new cases of colon and rectum cancer in Denmark are entered prospectively into this nationwide database founded by the DCCG and hosted by the RKKP. The database holds virtually all (>98%) patients diagnosed with colon cancers in Denmark since May 2001. The database has a high completeness of data on patient characteristics, diagnostic workup, treatment, short-term outcomes and histopathology. Since 2016, all patients have been assigned a clinical disease stage (cTNM) based on the diagnostic investigations before treatment and the assessment and discussion in the MDT.

2.2. Data Collection

We extracted 9167 patients classified by the surgeons as having primary colon cancer, diagnosed during the calendar years 2016–2019 and treated with an elective operative procedure with curative intent. Patients were excluded if the operative procedure did not
include formal bowel resection and thus did not produce a resection specimen for histopathological examination (n = 499). We also excluded patients in whom the current definitive procedure had been preceded by a previous emergent procedure (n = 424) or local resection of a malignant polyp (n = 739), i.e., in whom the quality of preoperative imaging might not be optimal. Patients in whom the information on synchronous tumors was either missing or affirmative (n = 429), or whose tumor was recorded by the pathologist as situated in the rectum (n = 67), were also excluded.

To ascertain the location of the tumor in question, we conducted the following validation procedure: Tumor locations were classified as right-sided or left-sided, defining midgut tumors (i.e., caecum, ascending colon, right colonic flexure and transverse colon) as right-sided and hindgut tumors (i.e., left flexure, descending colon, and sigmoid colon) as left-sided. Tumors were subsequently allocated to either the right-sided or left-sided group if the tumor location recorded by the surgeon and the pathologist agreed with regard to side (n = 6830), or if the surgeon had recorded the tumor location as “unspecified”, but the pathologist had recorded a specific location compatible with the operative procedure recorded (n = 8). Tumors were defined as transitional if regarded by the surgeon as situated in the transverse colon, and by the pathologist as situated in the left flexure, or vice versa (n = 60). The remaining 111 patients were excluded owing to missing or doubtful tumor location.

Finally, we excluded patients in whom information on neoadjuvant treatment (n = 277), or distant metastasis at the time of diagnosis (n = 519), was either missing or affirmative. Thus, 6102 patients remained for analysis: 3610 right-sided and 2441 left-sided, whereas 51 had a tumor on the midgut/hindgut transition.

2.3. Diagnostic Tests

National guidelines are in place for diagnosis and treatment of colorectal cancer in Denmark. A thoracoabdominal CT is the standard imaging modality for staging in colon cancer before treatment, although sometimes it is deemed necessary to add other imaging techniques, such as ultrasonography or positron emission tomography (PET).

The imaging techniques used for preoperative staging used to be recorded in the DCCG database, but this practice was discontinued in the summer of 2019, leaving missing values in 1133 patients (19%) of the present cohort. Since an abdominal CT was recorded in >97% of patients from the years 2016–2018, we assume that CT scans have been performed in nearly all patients. No details on the technical aspects of the imaging used are available in the DCCG database, and the data registered before 2019 show that modalities other than CT have been applied in 2–3% of patients. It is important, therefore, to understand that the present study is an assessment of the overall diagnostic performance of the MDT rather than of any particular imaging modality. The gold standard (histopathological examination) and MMR analyses were also assumed to be conducted according to national guidelines. MMR deficiency (dMMR) was regarded as present if any of the individual markers (MLH1, MSH2, MSH6 and PMS2) were deficient.

2.4. Data Analysis

We used descriptive methods to summarize baseline data. Overall measures of accuracy (sensitivity, specificity and positive predictive value (PPV), negative predictive value (NPV), false positive rate (FPR), false negative rate (FNR), false discovery rate (FDR) and false omission rate (FOR)) were estimated with exact 95% confidence intervals (CI). We focused on the ability to detect early vs. advanced tumor stage and aggregated T-categories into T0–2 vs. T3–4 and N-categories into N0 vs. N+.

We selected FPR and FNR as our main parameters of interest, since they imply a direct comparison of the diagnostic method with the gold standard and are independent of disease prevalence. They were calculated separately for the T-category (T-FPR, T-FNR) and the N-category (N-FPR, N-FNR). FPR and FNR were cross-tabulated against MMR status and other plausible predictors for inaccurate staging (age, sex, BMI, comorbidity as
measured by the Charlson score (CCI), histopathology, tumor location (right vs. left) and discussion at an MDT meeting) and subsequently regressed on selected predictors in univariate and multivariate logistic regression analyses.

FDR (=1-PPV) and FOR (=1-NPV) may be more readily useful to the clinician in decision making and patient counseling because they provide a direct answer to the clinical question: “What is the chance that my assessment is wrong?”. These statistics were cross-tabulated against significant predictors.

2.5. Statistical Analysis

All analyses and data management were performed using STATA Statistical Software (version 16, STATA Corporation, 4905 Lakeway Drive, College Station, Texas, USA). Final conclusions were based on a significance level of 0.01, although higher levels (0.2, 0.05) were used for exploration and variable selection. Confidence intervals (CI) are 95%.

3. Results

3.1. Patients and Tumor Characteristics

A total of 6102 patients were analyzed ($n = 3161$ (52%) men and $n = 2941$ (48%) women). Patient, tumor and treatment characteristics are described in Table 1. Table 2 shows overall measures of accuracy.

Table 1. Baseline characteristics of 6102 patients with colon cancer.

| Characteristic                        | Quantity       | Missing (%) |
|--------------------------------------|----------------|-------------|
| Age (median, range)                  | 72 (23–97)     | -           |
| Sex ($n$, %)                         |                | -           |
| Female                               | 2941 (48%)     |             |
| Male                                 | 3161 (52%)     |             |
| BMI (kg/m²) (median, IQR)            | 26 (23–29)     | 118 (2%) *  |
| Charlson score (CCI)                 |                | -           |
| 0 ($n$, %)                           | 2728 (45%)     |             |
| 1                                    | 858 (14%)      |             |
| 2                                    | 1526 (25%)     |             |
| 3+                                   | 990 (16%)      |             |
| Tumor side                           |                | -           |
| Right ($n$, %)                       | 3610 (59%)     |             |
| Left                                 | 2441 (40%)     |             |
| Transition                           | 51 (1%)        |             |
| Preoperative clinical T-category (cT) | 947 (16%)     |             |
| cT0 ($n$, % of non-missing)          | 66 (1%)        |             |
| cT1                                  | 444 (9%)       |             |
| cT2                                  | 1760 (34%)     |             |
| cT3                                  | 2413 (47%)     |             |
| cT4                                  | 472 (9%)       |             |
| Preoperative clinical N-category (cN) | 838 (14%)     |             |
| cN0 ($n$, % of non-missing)          | 3067 (58%)     |             |
| cN1                                  | 1472 (28%)     |             |
| cN2                                  | 725 (14%)      |             |
| Histopathology                       |                | 3 (0%)      |
| Adenocarcinoma NOS ($n$, % of non-missing) | 4899 (80%) |             |
| Low differentiated carcinoma         | 394 (6%)       |             |
| Mucinous carcinoma                   | 692 (11%)      |             |
| Other **                             | 114 (2%)       |             |
MMR status                        199 (3%)  
Deficient (dMMR) (n, % of non-missing) 1425 (24%)  
Proficient (pMMR)                  4478 (76%)  
* Including 17 BMI values discarded on suspicion of registration errors (weight < 10 kg, height > 250 cm, BMI > 50). ** Signet-cell, undifferentiated, or medullary.

Table 2. Overall measures of accuracy, clinical vs. histopathological category in colon cancer.

| Measure      | Calculated | 95% CI * |
|--------------|------------|----------|
| T-Category (T0–2 vs. T3–4)—All Patients |            |          |
| Sensitivity  | 0.68       | 0.66     | 0.69     |
| Specificity  | 0.78       | 0.76     | 0.80     |
| PPV          | 0.90       | 0.89     | 0.91     |
| NPV          | 0.46       | 0.44     | 0.48     |
| FPR          | 0.22       | 0.20     | 0.24     |
| FNR          | 0.32       | 0.31     | 0.34     |
| FDR          | 0.10       | 0.09     | 0.11     |
| FOR          | 0.54       | 0.52     | 0.56     |

| Measure      | Calculated | 95% CI * |
|--------------|------------|----------|
| N-category (N0 vs. N+)—All Patients |            |          |
| Sensitivity  | 0.55       | 0.53     | 0.57     |
| Specificity  | 0.66       | 0.64     | 0.67     |
| PPV          | 0.47       | 0.45     | 0.49     |
| NPV          | 0.72       | 0.71     | 0.74     |
| FPR          | 0.34       | 0.33     | 0.36     |
| FNR          | 0.45       | 0.43     | 0.47     |
| FDR          | 0.53       | 0.51     | 0.55     |
| FOR          | 0.28       | 0.26     | 0.29     |

* Confidence interval.

3.2. FPR, FNR, FDR and FOR

Table 3 shows unadjusted logistic regression of FPR and FNR. In the unadjusted logistic regression, T-FPR seemed to increase slightly with age (p < 0.2), albeit with an odds ratio (OR) very close to 1. T-FNR increased with male sex and comorbidity (both as a dichotomous and continuous variable) at the p < 0.2 level and decreased significantly with histopathological poor differentiation and dMMR status at the p < 0.001 level. N-FPR decreased with male sex, discussion at an MDT meeting (p < 0.2) and comorbidity (p < 0.001) and increased significantly with dMMR status, right-sided tumors and histopathology other than adenocarcinoma not otherwise specified (NOS) (p < 0.001). N-FNR seemed to increase somewhat with comorbidity and an MDT meeting (p < 0.2) and decrease significantly with right-sided tumors, dMMR status and histopathology other than adenocarcinoma NOS (p < 0.001).

Before proceeding with adjusted analyses, the importance of sidedness and MMR status was further explored by cross-tabulations. Significant associations were found between dMMR status and sex (66% females), sidedness (92% right-sided tumors) and histopathology (45% other than adenocarcinoma NOS vs. 11% in the pMMR group). Similarly, nodal involvement was less common among dMMR patients (27% vs. 38% in pMMR patients) and somewhat more common in right-sided than in left-sided pMMR tumors (40% vs. 36%). Right-sided tumors were also more often locally advanced (T3–4) (75%) than left-sided tumors (67%).

For the adjusted analyses, we selected sidedness, dMMR status and histopathology as our predictors of interest, and age, sex, BMI and MDT meeting as adjusting factors.
Comorbidity as measured by the CCI score was included among the potential confounders, since CCI is not an exact measure of all present comorbidities and may not be as unequivocal and simple as the predictors of interest.

Baseline logistic regression models with T-FPR, T-FNR, N-FPR and N-FNR as dependent variables and the abovementioned potential confounders as covariates were constructed, and the predictors of interest were entered one at a time and in combination to provide adjusted analyses.

In the adjusted analyses, none of the predictors of interest showed a significant association with T-FPR.

T-FNR was significantly decreased with low tumor differentiation (with OR estimates ranging from 0.47 to 0.52) and dMMR (OR, 0.64–0.72), but not with sidedness. N-FPR was significantly increased by right-sidedness (OR, 1.48–1.73), dMMR (OR, 1.41–1.74) and low tumor differentiation (OR, 1.62–1.87), although histopathology became statistically insignificant when the other predictors were introduced. N-FNR was significantly decreased with right-sidedness (OR, 0.44), dMMR (OR, 0.59) and low tumor differentiation (OR, 0.46–0.57), although only right-sidedness remained significant (OR, 0.48–0.49) when the two other predictors were introduced.

Empirical data for FPR, FNR, FDR and FOR are tabulated against the two persistent predictors (sidedness and MMR status) in Table 4. The $n$ values in the table are the denominators of the statistic in question and reflect the varying size of the subgroups. Some are rather small (e.g., left-sided dMMR tumors), and this explains the varying width of the confidence intervals. Incorrect preoperative staging was common, particularly in terms of T understaging and N overstaging. The latter was pronounced for dMMR patients.

### Table 3. Unadjusted logistic regression analysis of accuracy on predictors.

| Variable                        | OR *     | p    | 95% CI ** |
|---------------------------------|----------|------|-----------|
| **T-category—false positive rate** |          |      |           |
| Age                             | 1.0179   | 0.014 | 1.0036    | 1.0324    |
| Sex                             | 1.0043   | 0.974 | 0.7758    | 1.3000    |
| BMI                             | 0.9877   | 0.371 | 0.9612    | 1.0149    |
| Comorbidity (+/-)               | 0.9007   | 0.430 | 0.6948    | 1.1676    |
| Comorbidity (cont)              | 0.9664   | 0.447 | 0.8848    | 1.0554    |
| MDT meeting                     | 0.8558   | 0.298 | 0.6385    | 1.1473    |
| Side (left vs. right)           | 0.8546   | 0.239 | 0.6577    | 1.1103    |
| Histopathology                  |          |      |           |
| -Adenocarcinoma NOS             | 1        |      |           |
| -Low differentiated             | 1.2222   | 0.541 | 0.6427    | 2.3244    |
| -Mucinous                       | 1.6667   | 0.554 | 0.7004    | 3.9432    |
| -Other                          | 3.6667   | 0.025 | 1.1726    | 11.4651   |
| dMMR ***                        | 1.3334   | 0.425 | 0.8833    | 1.5415    |
| **T-category—false negative rate** |          |      |           |
| Age                             | 0.9958   | 0.208 | 0.9893    | 1.0023    |
| Sex                             | 1.1145   | 0.120 | 0.9721    | 1.2777    |
| BMI                             | 1.0090   | 0.205 | 0.9951    | 1.0231    |
| Comorbidity (+/-)               | 1.1446   | 0.054 | 0.9975    | 1.3135    |
| Comorbidity (cont)              | 1.0560   | 0.015 | 1.0105    | 1.1036    |
| MDT meeting                     | 1.0608   | 0.502 | 0.8929    | 1.2602    |
| Side (left vs. right)           | 1.0338   | 0.646 | 0.8972    | 1.1912    |
| Histopathology                  |          |      |           |
| -Adenocarcinoma NOS             | 1        |      |           |
| -Low differentiated             | 0.4717   | <0.001 | 0.3492    | 0.6374    |
Table 4. Crosstabulations of false positive rates, false negative rates, false discovery rates and false omission rates against tumor sidedness and mismatch repair status.

| Category | Diagnostic Test vs. Gold Standard | Rate of Faulty Preoperative Staging |
|----------|----------------------------------|-------------------------------------|
|          | False positive rate (=1-specificity) | False discovery rate (=1-PPV) |
|          | (Percent, with 95% CI in parentheses) | (Percent, with 95% CI in parentheses) |
| T3–4 vs. T0–2 | pMMR * | dMMR ** | pMMR | dMMR |
| Tumor location | | | | |
| Left-sided | 21% (18–25%) | 11% (3–27%) | 12% (10–14%) | 8% (2–19%) |
| (n = 559) | (n = 35) | (n = 987) | (n = 52) |
| Right-sided | 22% (18–26%) | 25% (20–31%) | 10% (8–12%) | 9% (7–12%) |
| (n = 441) | (n = 255) | (n = 1021) | (n = 695) |
| False negative rate (=1-sensitivity) | | | False omission rate (=1-NPV) |
| (Percent, with 95% CI in parentheses) | | | (Percent, with 95% CI in parentheses) |
| Tumor location | pMMR | dMMR | pMMR | dMMR |
| Left-sided | 33% (30–35%) | 23% (13–35%) | 49% (46–52%) | 31% (18–47%) |
| (n = 1295) | (n = 62) | (n = 867) | (n = 45) |
| Right-sided | 36% (33–38%) | 26% (23–29%) | 60% (56–63%) | 54% (49–59%) |
| (n = 1434) | (n = 853) | (n = 854) | (n = 413) |

* Odds ratio. ** Confidence interval. *** Mismatch repair deficient.
**Table 1:**

| Tumor location | pMMR | dMMR |
|----------------|------|------|
| **False positive rate (=1-specificity)** (Percent, with 95% CI in parentheses) | 27% (24–29%) | 36% (26–47%) |
| (n = 1216) | (n = 84) |
| **False discovery rate (=1-PPV)** (Percent, with 95% CI in parentheses) | 52% (48–56%) | 77% (61–89%) |
| (n = 627) | (n = 39) |

| Tumor location | pMMR | dMMR |
|----------------|------|------|
| **False negative rate (=1-sensitivity)** (Percent, with 95% CI in parentheses) | 57% (53–61%) | 53% (29–76%) |
| (n = 698) | (n = 19) |
| **False omission rate (=1-NPV)** (Percent, with 95% CI in parentheses) | 31% (28–33%) | 16% (8–27%) |
| (n = 1287) | (n = 64) |

* MMR deficient. ** MMR proficient.

### 4. Discussion

The aim of this study was to assess the impact of MMR deficiency and other patient and tumor characteristics on the accuracy of preoperative T and N staging in colon cancer. We found a significant and persistent association between dMMR and overestimation of the N-category, but we also found a significant impact of histopathology and tumor sidedness. Reactive lymph node enlargement in dMMR cancers is to be expected, because inability to repair mismatch results in accumulation of mutations, leading to the production of immune-response-eliciting proteins [18,19]. Additionally, there is a growing interest in regarding right- and left-sided cancers as distinct biological and clinical entities [20–29].

FPR and FNR were chosen as dependent variables since they imply direct comparisons of the diagnostic method and the gold standard and are independent of disease prevalence (in casu T3–4 and N+). However, these traditional measures of accuracy are often perceived by the average clinician as rather indirect indicators of the reliability of the diagnostic method. To translate our findings into figures that are easy to understand in a clinical context, we also calculated FDR and FOR, which are shown in Table 4. FDR and FOR may be regarded as the percentage of clinical T- and N-categories that ultimately turn out to be wrong. It may be noted that the importance of sidedness for N staging seems to fade or even reverse when results are presented as FDR and FOR, whereas the differences between dMMR and pMMR tumors become more pronounced. This may be explained by the dependence of FDR and FOR on prevalence. For example, increasing prevalence (e.g., of N+ status) tends to attenuate the effect of FPR on FDR, whereas decreasing prevalence tends to enhance it. The data shown in Table 4 are consistent with this explanation, when the differences in T- and N-categories (i.e., the prevalence of T3–4 and N+) between right- and left-sided tumors, and dMMR and pMMR tumors, are taken into consideration. This observation exemplifies the complex interplay of the determinants of test performance and emphasizes the importance of the clinical setting on its real-life effectiveness.

In this study, we found a sensitivity of 68% and specificity of 78% for the advanced cT-category (Table 2). We have no information on the expertise of the radiologist, and in general, there is limited information available on the importance of the radiologist’s level of expertise for accurate staging. CT staging can be challenging due to the anatomic structures and bowel movement and requires experience. Hong et al. compared performance between radiologists receiving feedback and others receiving no feedback and found better performance after feedback [30]. On the other hand, a meta-analysis found that magnetic resonance imaging (MRI) can reliably distinguish T1–T2 from T3–T4 (sensitivity 96%
and specificity 70%) [31], suggesting that MRI may have potential to replace CT as the standard modality for colon cancer in the future.

This study has some limitations. Formally, the study is retrospective, and for some variables, the number of missing data is not negligible. In addition, we have no information on the actual scanning dates, the skill level of the radiologists and any variation in techniques and protocols. A strength of the current study, on the other hand, is the very large, population-based dataset based on prospectively registered data from a national database. Further strengths of the current study are that routine data on MMR were available in most patients, and more generally, that all data were routinely collected and therefore as unbiased and representative for a real-life clinical setting as possible.

In summary, we showed with prevalence-independent statistics that MMR status in particular, but also other clinical and biological characteristics, may influence the accuracy of the preoperative staging. We also found, however, that in the everyday clinical setting, the importance of some of these factors may be further modified by the mere prevalence of the pathology in question. Table 4 presents empirical data from our study population in a manner that should be easy to understand and apply in a clinical setting.

5. Conclusions

In conclusion, MMR deficiency, but also tumor sidedness and to some degree histopathological type, impacts the accuracy of preoperative staging of colon cancer. For everyday clinical staging, MMR status should be taken into consideration.

Author Contributions: Conceptualization, H.B.R. and T.F.H.; methodology, T.F.H., H.B.R., J.L., S.R.R. and M.R.P.; formal analysis, H.B.R.; resources, T.F.H., H.B.R., J.L., S.R.R. and M.R.P.; writing—original draft preparation, M.R.P., and H.B.R.; writing—review and editing, T.F.H., H.B.R., J.L., S.R.R. and M.R.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved locally by the local National Data Protection Agency. According to national law, the current study did not require patient consent or approval by the National Health Research Ethics Committee since there was no biomedical intervention. Permission to use the data was granted by the national quality assurance authority (Regionernes Kliniske Kvalitetsudviklingsprogram, RKKP) (No. DCCG-2020-10-14).

Informed Consent Statement: As this is a retrospective registry study, informed consent is not necessary.

Data Availability Statement: The data are publicly available in the Danish DCCG database.

Acknowledgments: The authors appreciate the kind permission of the RKKP and DCCG to use data from the national database. We also wish to thank the statistical advice team at the Open Patient Data Exploratory Network (OPEN) at Odense University Hospital, Region of Southern Denmark, for valuable feedback and advice on the data analysis.

Conflicts of Interest: The authors declare no conflicts of interest.

References
1. Ingeholm, P. Landsdækkende Database for Kræft i Tyk- og Endetarm (dccg.dk) Klinisk Rapport. 2018. Available online: https://www.sundhed.dk/content/cms/81/4681_dccg-klinisk-basisrapport-2018.pdf (accessed on 1 April 2021).
2. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34, doi:10.3322/caac.21551.
3. Leufkens, A.M.; van den Bosch, M.A.J.; van Leeuwen, M.S.; Siersema, P.D. Diagnostic accuracy of computed tomography for colon cancer staging: A systematic review. Scand. J. Gastroenterol. 2011, 46, 887–894, doi:10.3109/00365521.2011.574732.
4. Choi, A.H. Nelson, R.A.; Schoelhammer, H.F.; Cho, W.; Ko, M.; Arrington, A.; Oxner, C.R.; Fakhri, M.; Wong, J.; Sentovitch, J.; et al. Accuracy of computed tomography in nodal staging of colon cancer patients. World J. Gastrointest. Surg. 2015, 7, 116–22, doi:10.4240/wjgs.v7.i7.116.
5. Olsen, A.S.F.; Gundestrup, A.K.; Kleif, J.; Thanon, T.; Bertelsen, C.A. Accuracy of preoperative staging with multidetector computed tomography in colon cancer. Color. Dis. 2020, 1–9, doi:10.1111/codi.15415.
6. Juchems, M.S.; Ernst, A.S.; Kornmann, M.; Barth, T.F.; Kramer, K.; Brambs, H.-J.; Aschoff, A.J. Value of MDCT in Preoperative Local Staging of Rectal Cancer for Predicting the Necessity for Neoadjuvant Radiochemotherapy. RöFo-Fortschr. Auf Dem Geb. Der Röntgenstrahlen Der Bildgeb. Verfahr. 2009, 181, 1168–1174, doi:10.1055/s-0028-1109356.

7. Erbs, E.; Rafaeelsen, S.R.; Lindberjerg, J.; Jensen, L.H.; Hansen, T.F. The impact of mismatch repair status to the preoperative staging of colon cancer: Implications for clinical management. Color. Cancer 2020, 9, CRC20, doi:10.2217/crc-2020-0001.

8. Sjövall, A.; Blomqvist, L.; Egenvall, M.; Johansson, H.; Martling, A. Accuracy of preoperative T and N staging in colon cancer - a national population-based study. Color. Dis. 2016, 18, 73–79, doi:10.1111/codi.13091.

9. Korsbakke, K.; Dahlbäck, C.; Karlsson, N.; Zackrisson, S.; Buchwald, P. Tumor and nodal staging of colon cancer: Accuracy of preoperative computed tomography at a Swedish high-volume center. Acta Radiol. 2019, 8, 205846011988871, doi:10.1177/2058460119888713.

10. Dam, C.; Lindberjerg, J.; Jakobsen, A.; Jensen, L.H.; Rahr, H.; Rafaeelsen, S.R. Local staging of sigmoid colon cancer using MRI. Acta Radiol. Open 2017, 6, 205846011772095.

11. Squillacii, E.; Manenti, G.; Mancino, S.; Ciccio, C.; Calabrìa, F.; Danielli, R.; Schillaci, O.; Simonetti, G. Staging of colon cancer: Whole-body MRI vs. whole-body PET-CT—initial clinical experience. Abdom. Imaging 2008, 33, 667–688, doi:10.1007/s00261-007-9347-5.

12. Rollevt, E.; Holm, T.; Glimelius, B.; Lörinc, E.; Blomqvist, L. Potentials of high resolution magnetic resonance imaging versus computed tomography for preoperative local staging of colon cancer. Acta Radiol. 2013, 54, 722–730, doi:10.24048/s41519-13484018.

13. Park, S.Y.; Cho, S.H.; Lee, M.A.; Yoon, G.; Kim, H.J.; Park, J.S.; Lee, S.M.; Shin, K.-M.; Kim, G.C.; et al. Molecular differences in the microsatellite stable phenotype between left-sided and right-sided colorectal cancer. BMC Cancer 2020, 21, 282, doi:10.1186/s12885-021-07942-1.

14. Li, J.; Zhang, Y.; Xu, Q.; Wang, G.; Jiang, L.; Wei, Q.; Qin, H.; et al. The impact of primary tumor site differs according to the KRAS mutation status. Cancer Manag. Res. 2021, 13, 2925–2935, doi:10.2147/cmr.s29885.

15. Lee, C.; Malietzis, G.; Askari, A.; Bernardo, D.; Al-Hassi, H.; Clark, S. Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic review. Eur. J. Surg. Oncol. 2015, 41, 300–308, doi:10.1016/j.ejso.2014.11.001.

16. Takahashi, Y.; Sugai, T.; Habano, W.; Ishida, K.; Eizuka, M.; Otsuka, K.; Sasaki, A.; Matsumoto, T.; Morikawa, T.; Unno, M.; et al. Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: The Streamline diagnostic accuracy studies. Health Technol. Assess. 2019, 23, 1–270, doi:10.3310/hta23660.

17. Song, Y.; Wang, Y.; An, J.; Fu, P. Local Staging of Colon Cancer: A Cross-Sectional Analysis for Diagnostic Performance of Magnetic Resonance Imaging and by Experience. Cancer Investig. 2021, 39, 379–389, doi:10.1080/07357907.2021.1897610.

18. Ingelholm, P.; Götengur, I.; Iversen, L.H. Danish Colorectal Cancer Group Database. Clin. Epidemiol. 2016, 8, 465–468, doi:10.2147/ceplh.s99481.

19. Xiao, J.; Li, W.; Huang, Y.; Huang, M.; Li, S.; Zhai, X.; Zhao, J.; Gao, C.; Xie, W.; Qin, H.; et al. Next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer. BMC Cancer 2021, 21, 282, doi:10.1186/s12885-021-07942-1.

20. Li, J.; Zhang, Y.; Xu, Q.; Wang, G.; Jiang, L.; Wei, Q.; Lu, C.; Chen, L.; Ying, J. Systemic Inflammatory Markers of Resectable Colorectal Cancer Patients with Different Mismatch Repair Gene Status. Cancer Manag. Res. 2021, 13, 2925–2935, doi:10.2147/cmr.s29885.

21. Lee, C.; Malietzis, G.; Askari, A.; Bernardo, D.; Al-Hassi, H.; Clark, S. Is right-sided colon cancer different to left-sided colorectal cancer? – A systematic review. Eur. J. Surg. Oncol. 2015, 41, 300–308, doi:10.1016/j.ejso.2014.11.001.

22. Turner, M.C.; Becerra, D.; Sun, Z.; Watson, J.; Leung, K.; Migaly, J.; Mantyh, C.R.; Blazer, D.G. The side of the primary tumor affects overall survival in colon adenocarcinoma: An analysis of the national cancer database. Tech. Coloproctolog 2019, 23, 537–544, doi:10.1015/1-09-01997-w.

23. Margonis, G.A.; Amini, N.; Buettner, S.; Kim, Y.; Wang, J.; Andreatos, N.; Wagner, D.; Sasaki, K.; Beer, A.; Kamphues, C.; et al. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status. A Study by the International Genetic Consortium for Colorectal Liver Metastasis. Ann. Surg. 2021, 273, 1165–1172, doi:10.1097/sla.0000000000003504.

24. Mukund, K.; Syuluykina, N.; Ramamoorthy, S.; Subramaniam, S. Right and left-sided colon cancers—Specificity of molecular mechanisms in tumorigenesis and progression. BMC Cancer 2020, 20, 317, doi:10.1186/s12885-020-06784-7.

25. Mukkamalla, S.K.R.; Somasundar, P.; Rathore, B. Prognostic Impact of Tumor Status, Nodal Status and Tumor Sidedness in Metastatic Colon Cancer. Cures. 2020, 12, e1144, doi:10.7759/cures.11444.

26. Azar, I.; Al Masalmeh, N.; Esfandiarifard, S.; Virk, G.; Kiwan, W.; Shields, A.F.; Mehdi, S.; Philip, P.A. The impact of primary tumor sidedness on survival in early-onset colorectal cancer by stage: A National Veterans Affairs retrospective analysis. Cancer Med. 2021, 10, 2987–2995, doi:10.1002/cam4.3757.

27. Li, K.-Z.; Yin, Y.-X.; Tang, Y.-P.; Long, L.; Xie, M.-Z.; Li, J.-L.; Ding, K.; Hu, B.-L. Construction of a long noncoding RNA-based competing endogenous RNA network and prognostic signatures of left- and right-side colon cancer. Cancer Cell Int. 2021, 21, 211, doi:10.1186/s12935-021-01901-3.

28. Yang, L.-P.; Wang, Z.-X.; Zhang, R.; Zhou, N.; Wang, A.-M.; Liang, W.; Wang, Z.-Q.; Luo, H.-Y.; Wang, F.; Liu, J.-W.; et al. Association between cigarette smoking and colorectal cancer sidedness: A multi-center big-data platform-based analysis. J. Transl. Med. 2021, 19, 150, doi:10.1186/s12967-021-02815-4.
29. Huang, Y.; Duanmu, J.; Liu, Y.; Yan, M.; Li, T.; Jiang, Q. Analysis of multi-omics differences in left-side and right-side colon cancer. *PeerJ* 2021, 9, e11433, doi:10.7717/peerj.11433.

30. Hong, E.K.; Castagnoli, F.; Gennaro, N.; Landolfi, F.; Pérez-Serrano, C.; Kurilova, I.; Roberti, S.; Beets-Tan, R. Locoregional CT staging of colon cancer: Does a learning curve exist? *Abdom. Radiol.* 2021, 46, 476–485, doi:10.1007/s00261-020-02672-7.

31. Nerad, E.; Lambrégts, D.M.; Kersten, E.L.; Maas, F.C.; Bakers, H.C.; van der Bosch, H.I.; Grabsch, R.G.; Beets-Tan, R.G.H.; Lahaye, M.J. MRI for Local Staging of Colon Cancer: Can MRI Become the Optimal Staging Modality for Patients with Colon Cancer? *Dis. Colon Rectum* 2017, 60, 385–392.